Cigna Beats Q4 Estimates but 2026 Outlook Falls Short as Drug Plan Overhaul Weighs on Profits
Cigna reports adjusted Q4 EPS of $8.08, beating estimates, but 2026 guidance of $30.25 disappoints Wall Street as the insurer restructures its pharmacy benefits business.